Kestra Medical Technologies, LTD. is a US-listed company in the health care equipment industry. Its financial year ends in April.
Loading chart…
Third-party market data · may be delayed
Under review: every model's value for Kestra Medical Technologies, LTD. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Kestra Medical Technologies, LTD. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to July 2026 was $107m. Free-cash-flow margin rose to -115.0% from -166.3% a year earlier. Operating margin widened to -134.5% from -175.9%. It passes 3 of our 6 financial-health checks.
Our model value for Kestra Medical Technologies is under review, so past values are not shown until it is resolved.
Source: 10-Q filed September 14, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Kestra Medical Technologies, LTD.'s trailing-twelve-month revenue grew 60.7% year on year, with a free-cash-flow margin of -115.0%.
Current signal Gross margin expanding: TTM gross margin reached 53.9%, up 10.4pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Kestra Medical Technologies, LTD. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$1.8 ~$2.1–$8.8 | Left out: out of range vs price (0.06x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Kestra Medical Technologies, LTD. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 | 2026 | Now |
|---|---|---|---|
| Share price | $24.06 | $20.72 | $29.81 |
| Market value | $591m | $1.1bn | $1.7bn |
| + Net debt (− = net cash) | −$196m | −$57m | $4m |
| Enterprise value | $395m | $1.1bn | $1.7bn |
| Multiples | |||
| Price / sales | 9.9x | 11.8x | 15.6x |
| Price / earnings | — | — | — |
| Price / free cash flow | — | — | — |
| EV / EBITDA | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Next results: December 14, 2026, after the close. Analysts expect revenue of $32m and EPS of −$0.60 (range −$0.61 to −$0.60) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.45 | −43% | $141m | +48% |
| Next | −$2.06 | +16% | $196m | +39% |
The consensus EPS forecast for the current fiscal year is +14.5% on 90 days ago. In the last 30 days, 0 analysts raised Kestra Medical Technologies, LTD.'s forecast and 2 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.14 | −$1.41 |
| 60 days ago | −$2.31 | −$2.02 |
| 30 days ago | −$2.31 | −$2.02 |
| 7 days ago | −$2.31 | −$2.06 |
| Now | −$2.45 | −$2.06 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | −$0.63 | −$0.46 | +26.7% |
| Apr 2026 | −$0.58 | −$0.49 | +15.8% |
| Jan 2026 | −$0.60 | −$0.40 | +32.6% |
| Oct 2025 | −$0.56 | −$0.45 | +19.8% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2026 to date |
|---|---|
| Return | |
| KMTS | +12% |
| Industry peers (median) | −15% |
| S&P 500 | +11% |
| Months that ended higher | |
| KMTS | 64% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| KMTS | −36% |
| S&P 500 | −9% |
Worst fall since March 6, 2025: 44% from April 2, 2025 to August 6, 2025. Getting back needed a 78% gain, reached on September 23, 2025, 48 days after the low.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| September 14, 2026 | +10.2% | −0.9% | +8.4% | +18.0% |
| July 14, 2026 | −0.6% | +0.8% | −10.2% | +13.1% |
| March 17, 2026 | +1.7% | −1.1% | +7.5% | +6.0% |
| December 11, 2025 | +6.7% | −0.8% | +10.7% | −10.1% |
| December 1, 2025 | −14.7% | −0.3% | −9.1% | −1.7% |
| September 11, 2025 | +20.0% | +0.8% | +38.5% | +20.9% |
| July 15, 2025 | −0.5% | −0.1% | +10.4% | +3.0% |
| April 14, 2025 | −0.6% | +0.7% | −1.2% | −7.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY25 Q4 | $59.8M |
| FY26 Q1 | $66.4M |
| FY26 Q2 | $74.3M |
| FY26 Q3 | $83.7M |
| FY26 Q4 | $95.1M |
| FY27 Q1 | $106.7M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY25 Q4 | -177.8% |
| FY26 Q1 | -175.9% |
| FY26 Q2 | -174.3% |
| FY26 Q3 | -171.5% |
| FY26 Q4 | -141.6% |
| FY27 Q1 | -134.5% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY25 Q4 | -168.1% |
| FY26 Q1 | -166.3% |
| FY26 Q2 | -152.9% |
| FY26 Q3 | -142.9% |
| FY26 Q4 | -122.6% |
| FY27 Q1 | -115.0% |
| Fiscal year | 2024 Apr 2024 | 2025 Apr 2025 | 2026 Apr 2026 | LTM Jul 2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 28 | 60 | 95 | 107 |
| Gross profit | 0 | 24 | 49 | 58 |
| EBITDA | −74 | −98 | −126 | −134 |
| Operating income | −85 | −106 | −135 | −144 |
| Net income | −94 | −114 | −132 | −150 |
| Diluted EPS | −$5.07 | −$5.13 | −$2.43 | −$2.68 |
| Growth (year on year) | ||||
| Revenue | — | +115.1% | +59.0% | +60.7% |
| Margins | ||||
| Gross margin | 1.3% | 40.5% | 51.4% | 53.9% |
| EBITDA margin | −264.3% | −164.5% | −132.5% | −125.7% |
| Operating margin | −305.8% | −177.8% | −141.6% | −134.5% |
| Net margin | −338.4% | −190.3% | −138.4% | −140.4% |
| Free-cash-flow margin | −303.7% | −168.1% | −122.6% | −115.0% |
| Cash flow | ||||
| Cash from operations | −72 | −78 | −82 | −88 |
| Capital spending | 12 | 23 | 35 | 35 |
| Free cash flow | −84 | −101 | −117 | −123 |
| Stock-based pay | 1 | 24 | 34 | 39 |
| Free cash flow after stock pay | −86 | −125 | −150 | −161 |
| Balance sheet | ||||
| Cash | 8 | 238 | 100 | 69 |
| Total debt | 43 | 41 | 43 | 72 |
| Net debt (negative = net cash) | 34 | −196 | −57 | 4 |
| Diluted shares | 20m | 25m | 54m | 56m |
| Quarter | 2025 Q2 Oct 2024 | 2025 Q3 Jan 2025 | 2025 Q4 Apr 2025 | 2026 Q1 Jul 2025 | 2026 Q2 Oct 2025 | 2026 Q3 Jan 2026 | 2026 Q4 Apr 2026 | 2027 Q1 Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 15 | 15 | 17 | 19 | 23 | 25 | 29 | 31 |
| Gross profit | 6 | 7 | 8 | 9 | 11 | 13 | 16 | 17 |
| EBITDA | −17 | −19 | −46 | −27 | −29 | −33 | −37 | −35 |
| Operating income | −19 | −21 | −48 | −29 | −32 | −35 | −39 | −38 |
| Net income | −20 | −22 | −52 | −26 | −33 | −34 | −39 | −44 |
| Diluted EPS | −$1.19 | −$1.25 | −$1.57 | −$0.50 | −$0.64 | −$0.61 | −$0.67 | −$0.75 |
| Growth (year on year) | ||||||||
| Revenue | — | — | — | +51.5% | +53.4% | +62.7% | +66.2% | +59.9% |
| Margins | ||||||||
| Gross margin | 39.6% | 43.4% | 44.3% | 45.7% | 50.6% | 52.6% | 54.8% | 56.5% |
| EBITDA margin | −117.4% | −124.0% | −269.1% | −138.6% | −130.2% | −133.5% | −129.3% | −113.0% |
| Operating margin | −130.1% | −136.5% | −279.8% | −149.1% | −140.7% | −141.6% | −137.4% | −121.6% |
| Net margin | −138.5% | −142.5% | −302.1% | −133.3% | −145.3% | −139.2% | −135.6% | −142.3% |
| Free-cash-flow margin | −153.0% | −146.2% | −182.5% | −177.8% | −113.5% | −114.7% | −99.1% | −131.2% |
| Cash flow | ||||||||
| Cash from operations | −18 | −18 | −24 | −26 | −18 | −18 | −19 | −32 |
| Capital spending | 4 | 4 | 7 | 8 | 7 | 10 | 10 | 8 |
| Free cash flow | −23 | −22 | −31 | −34 | −26 | −28 | −28 | −41 |
| Stock-based pay | 1 | 0 | 22 | 5 | 9 | 10 | 10 | 10 |
| Free cash flow after stock pay | −24 | −23 | −54 | −39 | −34 | −38 | −39 | −50 |
| Last 12 months unless stated | KMTS | XTNT | SMTI | CBLL | OWLT | OM | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $107m | $110m | $110m | $102m | $115m | $118m | $102m |
| Revenue growth, last 12 months | 60.7% | −14.3% | 13.0% | 31.7% | 28.2% | −1.3% | 9.3% |
| Revenue growth, 3-year average | — | 17.3% | 22.6% | — | 29.3% | −3.1% | 13.5% |
| Revenue growth, latest quarter | 59.9% | −35.0% | 9.0% | 32.5% | 29.9% | 0.7% | 10.5% |
| Gross margin | 53.9% | 59.4% | 93.0% | 88.9% | 54.8% | 41.8% | 61.1% |
| Operating margin | −134.5% | −9.6% | 7.7% | −68.6% | −6.3% | −56.1% | −8.7% |
| Operating margin, 3-year average | — | −7.3% | 2.2% | −65.1% | −17.9% | −83.8% | −17.9% |
| Net margin | −140.4% | −10.2% | −29.2% | −64.7% | −7.7% | −63.1% | −12.1% |
| Cash from operations / revenue | −82.2% | 0.5% | 5.2% | −53.0% | −6.8% | −32.5% | −2.1% |
| Free-cash-flow margin | −115.0% | −0.6% | 4.1% | −53.7% | −7.4% | −33.0% | −4.0% |
| Free-cash-flow margin, 3-year average | — | −6.2% | −0.1% | — | −14.1% | −70.2% | −7.0% |
| Stock pay / revenue | 36.2% | 2.7% | 4.5% | 16.1% | 11.2% | 13.0% | 6.3% |
| Change in share count | — | 4.0% | 0.3% | — | 72.6% | 311.4% | 4.0% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Bain Capital Investors LLC | $640M | 25.2M | 43.1% | 0.0% |
| FMR LLC | $141M | 5.5M | 9.5% | ▼ 3.5% |
| Price T Rowe Associates Inc | $126M | 5.0M | 8.5% | ▼ 16.8% |
| Andera Partners | $69.4M | 2.7M | 4.7% | ▲ 1.2% |
| Yu Fan | $58.1M | 2.3M | 3.9% | 0.0% |
| Brown Advisory Inc | $48.6M | 1.9M | 3.3% | ▲ 10.8% |
| Blackrock, Inc. | $47.5M | 1.9M | 3.2% | ▲ 10.4% |
| Eventide Asset Management, LLC | $36.8M | 1.4M | 2.5% | ▲ 0.1% |
| Vanguard Capital Management LLC | $29.9M | 1.2M | 2.0% | ▼ 3.1% |
| Alliancebernstein L.P. | $29.5M | 1.5M | 2.0% | ▲ 11.9% |
| Franklin Resources Inc | $28.6M | 1.1M | 1.9% | ▼ 9.6% |
| Omega Fund Management, LLC | $26M | 1.0M | 1.7% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kestra Medical Technologies, LTD.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Umberger Traci S See Remarks | October 21, 2026 | Sell pre-set plan | 3,596 | $28.09 | $101,017 |
| Umberger Traci S See Remarks | October 21, 2026 | Sell pre-set plan | 96,404 | $27.15 | $2.6M |
| Webster Brian Daniel See Remarks | October 20, 2026 | Sell pre-set plan | 1,684 | $29.89 | $50,338 |
| Webster Brian Daniel See Remarks | October 20, 2026 | Sell pre-set plan | 13,316 | $29.52 | $393,051 |
| Cohen Raymond W Director | September 30, 2026 | Sell | 3,330 | $29.28 | $97,504 |
| Kwo Elizabeth Director | September 21, 2026 | Sell | 4,010 | $24.26 | $97,283 |
| Ladone Mary Kay Director | September 8, 2026 | Sell | 3,908 | $25.20 | $98,482 |
| Reilly Kevin C Director | September 8, 2026 | Sell | 2,932 | $25.13 | $73,681 |
| Hanley Conor Director | September 8, 2026 | Sell | 5,694 | $25.25 | $143,774 |
| Schwartz Jeffrey Lawrence Director | September 8, 2026 | Sell | 3,890 | $25.18 | $97,950 |
| Webster Brian Daniel See Remarks | August 17, 2026 | Sell pre-set plan | 15,000 | $27.48 | $412,200 |
| Mahboob Vaseem Chief Financial Officer | August 7, 2026 | Sell pre-set plan | 25,787 | $25.87 | $667,110 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around December 10, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
